Philadelphia-negative acute lymphoblastic leukemia (Ph-negative ALL) is a subtype of acute lymphoblastic leukemia (ALL) that does not carry the Philadelphia chromosome (a translocation between chromosomes 9 and 22, t(9;22), producing the BCR-ABL1 fusion gene).
This subtype makes up the majority of ALL cases in children, and about half of adult ALL cases.
BCR-ABL1 fusion gene (the “Philadelphia chromosome”), which is found in about 20-25% of adult ALL cases and 3-5% of pediatric cases.
The absence of this genetic abnormality significantly impacts prognosis and treatment approach.
Children: ~75–80% of ALL cases are Ph-negative; prognosis generally favorable.
Adults: Higher proportion of Ph-positive disease, but still many are Ph-negative.
Ph-negative ALL is genetically heterogeneous, with several recurrent abnormalities: B-cell lineage ALL the most common.
Hyperdiploidy (extra chromosomes with favorable prognosis in children.
Hypodiploidy (loss of chromosomes with poor prognosis.
T-cell ALL: Often Ph-negative by definition; carries its own molecular drivers (NOTCH1, TAL1)
Symptoms are similar to other ALL subtypes:
Symptoms of marrow failure: anemia (fatigue), neutropenia (infections), thrombocytopenia (bleeding/bruising).
Organ infiltration: lymphadenopathy, hepatosplenomegaly, mediastinal mass (especially in T-ALL).
CNS involvement in some cases.
Diagnosis Peripheral blood smear & bone marrow biopsy: ≥20% lymphoblasts. Immunophenotyping: B-cell vs T-cell lineage. Cytogenetics/molecular testing: to rule out Ph-positive and identify prognostic markers. Lumbar puncture: check for CNS involvement.
Prognosis
Children generally better than adults.
Cytogenetic subtype-ETV6-RUNX1 and hyperdiploidy favorable; hypodiploidy or KMT2A rearrangements poor.
Minimal residual disease (MRD) after induction therapy is the strongest predictor of long-term outcome.
Treatment Induction chemotherapy (e.g., vincristine, corticosteroids, anthracycline, asparaginase).
Consolidation/intensification with high-dose methotrexate, cytarabine, asparaginase.
Maintenance therapy (mercaptopurine + methotrexate ± vincristine/steroids for 2–3 years).
CNS prophylaxis (intrathecal chemotherapy ± cranial irradiation).
Targeted therapies: Blinatumomab (CD19 BiTE). Inotuzumab ozogamicin (CD22 antibody-drug conjugate). CAR-T cell therapy (CD19-directed) in relapsed/refractory cases. Allogeneic stem cell transplantation (allo-HSCT): Considered for high-risk or relapsed patients, especially adults.
Generally has a better prognosis than Ph-positive ALL, especially in pediatric patients.
Does not respond to tyrosine kinase inhibitors (like imatinib) that are used for Ph-positive cases.
Treatment typically involves intensive chemotherapy protocols
Pediatric Ph-negative ALL has cure rates of 85-90%
Adult Ph-negative ALL has more variable outcomes, with 5-year survival rates around 40-50%.